Skip to main content

Table 4 Comparison between the Response and Non-Response Groups after rifaximin treatment at week 4

From: Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome

Clinical factors Response group
(n = 45)
Non-response group
(n = 33)
P value
Age (mean, years) 34.82 ± 9.04 33.58 ± 8.84 0.544
Gender (M/F) 31/14 21/12 0.627
LHBT (+/−) 18/27 8/25 0.145
GI symptoms (mean) 5.36 ± 3.27 13.79 ± 5.21 < 0.001
Abdominal discomfort 0.87 ± 0.89 2.45 ± 1.23 < 0.001
Abdominal distension 0.49 ± 0.70 1.67 ± 1.29 < 0.001
Abdominal pain 0.91 ± 0.93 2.27 ± 1.53 < 0.001
Defecatory urgency 1.09 ± 1.13 2.73 ± 1.26 < 0.001
Diarrhea 1.02 ± 0.97 2.42 ± 1.23 < 0.001
Incomplete evacuation 0.98 ± 1.03 2.33 ± 1.22 < 0.001
Quality of life (mean) 616.34 ± 84.06 545.34 ± 94.70 0.001
Physical Functioning 97.33 ± 4.47 94.85 ± 5.93 0.048
Role-physical 82.78 ± 24.90 67.42 ± 36.70 0.031
Bodily pain 77.34 ± 13.70 62.36 ± 19.88 < 0.001
General Health 59.22 ± 16.52 45.64 ± 16.70 0.001
Vitality 67.33 ± 15.06 61.67 ± 14.23 0.094
Social Functioning 85.63 ± 10.52 76.67 ± 19.98 0.012
Role-Emotional 76.30 ± 32.28 72.73 ± 30.57 0.621
Mental Health 70.40 ± 16.30 64.00 ± 18.08 0.112